

## DIASORIN S.P.A. – UPDATE 2023 ANNUAL CALENDAR OF CORPORATE EVENTS\*

**Saluggia, July 27, 2023** – Partially updating the notices submitted on December 1, 2022, please find below the new scheduled date for approval of the third quarter 2023 results.

### **Board of Directors**

|                         |  |
|-------------------------|--|
| <b>November 3, 2023</b> | <b>Third quarter 2023 results approval</b> |
|-------------------------|--|

\* Indicative dates subject to change. Any changes will be communicated without delay.

### **About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 39 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasoringroup.com](http://www.diasoringroup.com)

### **For additional information, please contact:**

**Riccardo Fava**  
Corporate Vice President Communication & Investor Relations  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Eugenia Ragazzo**  
Corporate Investor Relations & ESG Analyst  
[eugenia.ragazzo@diasorin.it](mailto:eugenia.ragazzo@diasorin.it)